
Genprex to Present at The MicroCap Conference
Mr. Varner will be available for one-on-one meetings. Interested investors may request a meeting time by contacting Stephanie Carrington at ICR, either by calling 646-277-1282 or via . For more information please visit www.genprex.com .
About Genprex, Inc.Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
About the MicroCap ConferenceThe MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors. For more information please visit: www.microcapconf.com or contact Tony Yu at .
Contact: Investors:
Stephanie Carrington
ICR Healthcare
646-277-1282
James Heins
ICR Healthcare
203-682-8251
View original content with multimedia: http://www.prnewswire.com/news-releases/genprex-to-present-at-the-microcap-conference-300625781.html
SOURCE Genprex, Inc.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- T-REX Launches Intelligence Layer To Fix Web3's Value Distribution Problem
- BTCC Exchange Maintains 143% Total Reserve Ratio In September 2025 Demonstrating Continued Financial Strength
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Raises Over $16 Million With More Than 720M Tokens Sold
- Superiorstar Prosperity Group Russell Hawthorne Highlights New Machine Learning Risk Framework
- R0AR Chain Announces $100,000 Community Rewards For Creators, Yappers, And Brand Evangelists
Comments
No comment